Cambridge, Massachusetts-based Moderna is one of the first companies to move a vaccine against COVID-19 into clinical trials.

An international team of researchers led by the University of Manchester developed a new antiviral using natural glucose derivatives called cyclodextrins – a type of sugar – which shows promise in treating a broad range of viruses including herpes simplex, respiratory syncytial virus, hepatitis C, HIV and Zika virus.

As an additional measure in the fight against Zika virus, the U.S. Food and Drug Administration announced that it has made available a panel of human plasma samples to aid in the regulatory evaluation of serological tests to detect recent Zika virus infection.

The first report on how the Zika virus affected U.S. territories showed that 5 percent of women with confirmed infections had babies with birth defects, U.S. health officials said.